Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Nanomedicine
share announcement

Personalized Nanomedicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (30 April 2019) | Viewed by 53947

Special Issue Editors

Dr. Cristina Fornaguera

E-Mail
Guest Editor
GEMAT, Bioengineering Department, IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain
Special Issues, Collections and Topics in MDPI journals
Dr. Maria José García Celma

E-Mail
Guest Editor
Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain

Special Issue Information

Dear Colleagues,

The design of nanosystems for biomedical applications has experienced an exponential increase in the last few decades. Year by year, novel delivery systems are developed in research laboratories with the aim to become advanced medicines in a near future. A wide range of nanotechnology applications in the biomedical field have been developed for drug delivery, diagnostics and theranostics or regenerative medicine purposes. Considering therapeutic applications, nanomedicines could be advantageous as novel personalized therapies, since they are versatile systems that can be designed tuning their properties depending on the final specific function: using tailored (or innovative) biomaterials, incorporating the required targeting moieties and loading the appropriate active principle (e.g., drugs or gene material), thus enabling the desired therapeutic action specifically at the target tissue or cell. Although multiple advantages are attributed to nanomedicines, the literature concerning the design of personalized therapies using systems at the nanometric scale is still limited. For this reason, this Special Issue was created with the aim to be a meeting point for all those scientists who work creating novel personalized therapies making use of nanosystems. All of them are encouraged to send contributions to show their research and demonstrate the utility of nanosystems as future personalized medicines.

Dr. Cristina Fornaguera
Dr. Maria José García Celma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nanomedicine
  • Nanomaterials
  • Nanosystems
  • Nanometric scale
  • Personalized therapies

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3112 KiB  
Article
Improved Labeling of Pancreatic Islets Using Cationic Magnetoliposomes
by Rita Sofia Garcia Ribeiro, Ashwini Ketkar-Atre, Ting Yin, Karim Louchami, Tom Struys, Ivo Lambrichts, Abdullah Sener, Willy Jean Malaisse, Marcel De Cuyper and Uwe Himmelreich
J. Pers. Med. 2018, 8(1), 12; https://doi.org/10.3390/jpm8010012 - 12 Mar 2018
Cited by 6 | Viewed by 8200
Abstract
Pancreatic islets (PIs) transplantation is an alternative approach for the treatment of severe forms of type 1 diabetes (T1D). To monitor the success of transplantation, it is desirable to follow the location of engrafted PIs non-invasively. In vivo magnetic resonance imaging (MRI) of [...] Read more.
Pancreatic islets (PIs) transplantation is an alternative approach for the treatment of severe forms of type 1 diabetes (T1D). To monitor the success of transplantation, it is desirable to follow the location of engrafted PIs non-invasively. In vivo magnetic resonance imaging (MRI) of transplanted PIs is a feasible cell tracking method; however, this requires labeling with a suitable contrast agent prior to transplantation. We have tested the feasibility of cationic magnetoliposomes (MLs), compared to commercial contrast agents (Endorem and Resovist), by labeling insulinoma cells and freshly isolated rat PIs. It was possible to incorporate Magnetic Ressonance (MR)-detectable amounts of MLs in a shorter time (4 h) when compared to Endorem and Resovist. MLs did not show negative effects on the PIs’ viability and functional parameters in vitro. Labeled islets were transplanted in the renal sub-capsular region of healthy mice. Hypointense contrast in MR images due to the labeled PIs was detected in vivo upon transplantation, while MR detection of PIs labeled with Endorem and Resovist was only possible after the addition of transfection agents. These findings indicate that MLs are suitable to image PIs, without affecting their function, which is promising for future longitudinal pre-clinical and clinical studies involving the assessment of PI transplantation. Full article
(This article belongs to the Special Issue Personalized Nanomedicine)
►▼ Show Figures

Figure 1

12 pages, 1782 KiB  
Article
Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors
by Koldo Urbiola, Laura Blanco-Fernández, Manfred Ogris, Wolfgang Rödl, Ernst Wagner and Conchita Tros de Ilarduya
J. Pers. Med. 2018, 8(1), 4; https://doi.org/10.3390/jpm8010004 - 09 Jan 2018
Cited by 16 | Viewed by 8534
Abstract
The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be overexpressed on the surface of a wide variety of tumor cells. Therefore, the peptides B6 (TfR specific) and GE11 (targeted to the EGFR) were linked to the PAMAM (polyamidoamine) structure [...] Read more.
The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be overexpressed on the surface of a wide variety of tumor cells. Therefore, the peptides B6 (TfR specific) and GE11 (targeted to the EGFR) were linked to the PAMAM (polyamidoamine) structure via a polyethylenglycol (PEG) 2 kDa chain with the aim of improving the silencing capacity of the PAMAM-based dendriplexes. The complexes showed an excellent binding capacity to the siRNA with a maximal condensation at nitrogen/phosphate (N/P) 2. The nanoparticles formed exhibited hydrodynamic diameters below 200 nm. The zeta potential was always positive, despite the complexes containing the PEG chain in the structure showing a drop of the values due to the shielding effect. The gene silencing capacity was assayed in HeLa and LS174T cells stably transfected with the eGFPLuc cassette. The dendriplexes containing a specific anti luciferase siRNA, assayed at different N/P ratios, were able to mediate a mean decrease of the luciferase expression values of 14% for HeLa and 20% in LS174T cells, compared to an unspecific siRNA-control. (p < 0.05). In all the conditions assayed, dendriplexes resulted to be non-toxic and viability was always above 75%. Full article
(This article belongs to the Special Issue Personalized Nanomedicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1206 KiB  
Review
Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment
by Stuart P. Atkinson, Zoraida Andreu and María J. Vicent
J. Pers. Med. 2018, 8(1), 6; https://doi.org/10.3390/jpm8010006 - 23 Jan 2018
Cited by 19 | Viewed by 18358
Abstract
Polymer therapeutics (PTs) provides a potentially exciting approach for the treatment of many diseases by enhancing aqueous solubility and altering drug pharmacokinetics at both the whole organism and subcellular level leading to improved therapeutic outcomes. However, the failure of many polymer-drug conjugates in [...] Read more.
Polymer therapeutics (PTs) provides a potentially exciting approach for the treatment of many diseases by enhancing aqueous solubility and altering drug pharmacokinetics at both the whole organism and subcellular level leading to improved therapeutic outcomes. However, the failure of many polymer-drug conjugates in clinical trials suggests that we may need to stratify patients in order to match each patient to the right PT. In this concise review, we hope to assess potential PT-specific biomarkers for cancer treatment, with a focus on new studies, detection methods, new models and the opportunities this knowledge will bring for the development of novel PT-based anti-cancer strategies. We discuss the various “hurdles” that a given PT faces on its passage from the syringe to the tumor (and beyond), including the passage through the bloodstream, tumor targeting, tumor uptake and the intracellular release of the active agent. However, we also discuss other relevant concepts and new considerations in the field, which we hope will provide new insight into the possible applications of PT-related biomarkers. Full article
(This article belongs to the Special Issue Personalized Nanomedicine)
►▼ Show Figures

Figure 1

2676 KiB  
Review
Personalized Nanomedicine: A Revolution at the Nanoscale
by Cristina Fornaguera and Maria José García-Celma
J. Pers. Med. 2017, 7(4), 12; https://doi.org/10.3390/jpm7040012 - 12 Oct 2017
Cited by 104 | Viewed by 18063
Abstract
Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near [...] Read more.
Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to a cohort of patients. In the present review, the properties and requirements of pharmaceutical dosage forms at the nanoscale, so-called nanomedicines, are been highlighted. An overview of the main current nanomedicines in pre-clinical and clinical development is presented, detailing the challenges to the personalization of these therapies. Next, the process of development of novel nanomedicines is described, from their design in research labs to their arrival on the market, including considerations for the design of nanomedicines adapted to the requirements of the market to achieve safe, effective, and quality products. Finally, attention is given to the point of view of the pharmaceutical industry, including regulation issues applied to the specific case of personalized medicine. The authors expect this review to be a useful overview of the current state of the art of nanomedicine research and industrial production, and the future opportunities of personalized medicine in the upcoming years. The authors encourage the development and marketing of novel personalized nanomedicines. Full article
(This article belongs to the Special Issue Personalized Nanomedicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop